On Tuesday, Cardiff Oncology Inc (NASDAQ: CRDF) was -4.85% drop from the session before settling in for the closing price of $2.68. A 52-week range for CRDF has been $2.01 – $5.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 24.32% over the last five years. When this article was written, the company’s average yearly earnings per share was at 16.87%. With a float of $59.79 million, this company’s outstanding shares have now reached $66.52 million.
The firm has a total of 33 workers. Let’s measure their productivity. In terms of profitability, gross margin is 55.7%, operating margin of -7112.72%, and the pretax margin is -6642.84%.
Cardiff Oncology Inc (CRDF) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cardiff Oncology Inc stocks. The insider ownership of Cardiff Oncology Inc is 10.13%, while institutional ownership is 36.18%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 16.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.85% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
You can see what Cardiff Oncology Inc (CRDF) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 249.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Analysing the last 5-days average volume posted by the [Cardiff Oncology Inc, CRDF], we can find that recorded value of 0.74 million was lower than the volume posted last year of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 16.92%. Additionally, its Average True Range was 0.22.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 5.79%, which indicates a significant decrease from 10.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.23% in the past 14 days, which was lower than the 125.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.32, while its 200-day Moving Average is $3.14. Now, the first resistance to watch is $2.66. This is followed by the second major resistance level at $2.77. The third major resistance level sits at $2.87. If the price goes on to break the first support level at $2.45, it is likely to go to the next support level at $2.35. Now, if the price goes above the second support level, the third support stands at $2.24.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are 66,526K outstanding shares of the company, which has a market capitalization of 169.64 million. As of now, sales total 680 K while income totals -45,430 K. Its latest quarter income was 150 K while its last quarter net income were -11,790 K.
